ReviewFrontiers in oncology2025
Sentinel lymph node biopsy omission in early-stage breast cancer: current evidence and clinical practice.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performance.Annals of surgical oncology · 2026Article
- Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent trials (e.g., SOUND, INSEMA) indicate that omitting SLNB in patients with small tumors, negative imaging, and favorable prognoses maintains outcomes, reduces complications, and improves quality of life (3,4). Specifically, the INSEMA trial demonstrated that patients who omitted SLNB experienced significantly lower rates of persistent lymphedema (1.8% vs. 5.7%), restriction of arm/shoulder mobility (2.0% vs. 3.5%), and pain with arm/shoulder movement (2.0% vs. 4.2%) compared to those undergoing SLNB. Consequently, guidelines now suggest omitting routine SLNB in elderly patients and those with very low-risk tumors(2). This review summarizes current evidence, eligible populations, theoretical rationale, controversies, and future directions regarding SLNB omission in early breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.